OSUCCC – JAMES GRAND ROUNDS

The 2017-18 OSUCCC – James Grand Rounds series continues on selected Fridays throughout the academic year. All lectures take place from 8-9 a.m. in James L035 (Wasserstrom Family Conference Room on the Conference Level) unless otherwise noted, with breakfast available at 7:45 a.m. The next lecture will take place on Friday, April 20. Below are the biosketches for the next presenters.

JUST ADDED! APRIL 20 – Peter Shields, MD, professor of Internal Medicine and of Epidemiology, and deputy director of The Ohio State University Comprehensive Cancer Center, will present “Cigarette and Electronic Cigarette Design Affecting Toxicity and Lung Cancer Risks: Influencing the FDA” at the Friday, April 20 Grand Rounds at 8 a.m. in Room 115 of the Biomedical Research Tower (NOTE LOCATION CHANGE).

Dr. Shields is co-principal investigator (using multi-PI mechanisms), along with Mary Ellen Wewers, PhD, MPH, professor emeritus of Health Behavior and Health Promotion, for The Ohio State University Tobacco Center of Regulatory Science, an NCI program project grant awarded in 2013. The grant examines the effects of removing filter ventilation on exposure and toxicity; perceptions and product choice, with Dorothy Hatsukami, PhD, professor of Psychiatry at the University of Minnesota; and the impact of a NIDA standardized research electronic cigarette on pulmonary toxicity using bronchoscopy with Mark Wewers, MD, professor of Pulmonary, Critical Care and Sleep Medicine at Ohio State.

Dr. Shields received his MD from Mount Sinai School of Medicine, and completed his medical oncology fellowship in a combined program at George Washington University and the National Cancer Institute. Prior to coming to Ohio State, Dr. Shields was a tenured section chief in the intramural program of the National Cancer Institute’s Laboratory of Human Carcinogenesis and later was a cancer center program leader and deputy director at Georgetown University.

Dr. Shields is a senior editor of the journal Cancer Epidemiology, Biomarkers and Prevention, and sits on the boards of several other journals. He is the chair of the NCCN Guidelines® Committee for Smoking Cessation and is a task force co-chair for the National Lung Cancer Roundtable. He has more than 240 publications focused on molecular epidemiology, tobacco and lung cancer, and a large number of those also focus on risk factors for breast cancer.

Credit: National Institutes of Health

MAY 4 – Norman E. “Ned” Sharpless, MD, director of the National Cancer Institute (NCI), will present at the Friday, May 4 Grand Rounds at 8 a.m. in L035 James.

Dr. Sharpless was officially sworn in as the 15th director of the National Cancer Institute (NCI) on October 17, 2017. Prior to his appointment, he served as the director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, a position he held since January 2014.

Dr. Sharpless was a Morehead Scholar at UNC–Chapel Hill and received his undergraduate degree in mathematics. He went on to pursue his medical degree from the UNC School of Medicine, graduating with honors and distinction in 1993. He then completed his internal medicine residency at the Massachusetts General Hospital and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston.

After two years on the faculty at Harvard Medical School, he joined the faculty of the UNC School of Medicine in the Departments of Medicine and Genetics in 2002. He became the Wellcome Professor of Cancer Research at UNC in 2012.

Dr. Sharpless is a member of the Association of American Physicians as well as the American Society for Clinical Investigation (ASCI), the nation’s oldest honor society for physician–scientists, and served on the ASCI council from 2011 to 2014. He was an associate editor of Aging Cell and deputy editor of the Journal of Clinical Investigation. He has authored more than 150 original scientific papers, reviews and book chapters and is an inventor on 10 patents. He co-founded two clinical-stage biotechnology companies: G1 Therapeutics and HealthSpan Diagnostics.

In addition to serving as director of the NCI, Dr. Sharpless continues his research in understanding the biology of the aging process that promotes the conversion of normal self-renewing cells into dysfunctional cancer cells. He has made seminal contributions to the understanding of the relationship between aging and cancer and in the preclinical development of novel therapeutics for melanoma, lung cancer and breast cancer.